• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗和手术治疗食管癌的条件生存。

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.

机构信息

Department of Surgery, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Cancer Centre Amsterdam, Amsterdam, the Netherlands.

Department of Radiotherapy, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Cancer Centre Amsterdam, Amsterdam, the Netherlands.

出版信息

Br J Surg. 2020 Jul;107(8):1053-1061. doi: 10.1002/bjs.11476. Epub 2020 Feb 3.

DOI:10.1002/bjs.11476
PMID:32017047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7317937/
Abstract

BACKGROUND

Conditional survival accounts for the time already survived after surgery and may be of additional informative value. The aim was to assess conditional survival in patients with oesophageal cancer and to create a nomogram predicting the conditional probability of survival after oesophagectomy.

METHODS

This retrospective study included consecutive patients with oesophageal cancer who received neoadjuvant chemoradiation followed by oesophagectomy between January 2004 and 2019. Conditional survival was defined as the probability of surviving y years after already surviving for x years. The formula used for conditional survival (CS) was: CS  = S /S , where S represents overall survival at x years. Cox proportional hazards models were used to evaluate predictors of overall survival. A nomogram was constructed to predict 5-year survival directly after surgery and given survival for 1, 2, 3 and 4 years after surgery.

RESULTS

Some 660 patients were included. Median overall survival was 44·4 (95 per cent c.i. 37·0 to 51·8) months. The probability of achieving 5-year overall survival after resection increased from 45 per cent directly after surgery to 54, 65, 79 and 88 per cent given 1, 2, 3 and 4 years already survived respectively. Cardiac co-morbidity, cN category, ypT category, ypN category, chyle leakage and pulmonary complications were independent predictors of survival. The nomogram predicted 5-year survival using these predictors and number of years already survived.

CONCLUSION

The probability of achieving 5-year overall survival after oesophagectomy for cancer increases with each additional year survived. The proposed nomogram predicts survival in patients after oesophagectomy, taking the years already survived into account.

摘要

背景

条件生存考虑了手术后已经存活的时间,可能具有额外的信息价值。目的是评估食管癌患者的条件生存,并创建一个预测食管癌手术后条件生存概率的列线图。

方法

本回顾性研究纳入了 2004 年 1 月至 2019 年间接受新辅助放化疗后行食管癌切除术的连续食管癌患者。条件生存定义为已经存活 x 年后再存活 y 年的生存概率。条件生存(CS)的计算公式为:CS=S/S,其中 S 代表 x 年时的总生存。Cox 比例风险模型用于评估总生存的预测因素。构建了一个列线图来直接预测手术后 5 年的生存率,并预测手术后 1、2、3 和 4 年的生存率。

结果

共纳入 660 例患者。中位总生存时间为 44.4(95%可信区间 37.0 至 51.8)个月。切除后达到 5 年总生存率的概率从手术后直接的 45%增加到分别已经存活 1、2、3 和 4 年时的 54%、65%、79%和 88%。心脏合并症、cN 分期、ypT 分期、ypN 分期、乳糜漏和肺部并发症是生存的独立预测因素。该列线图使用这些预测因素和已经存活的年数来预测 5 年生存率。

结论

食管癌手术后达到 5 年总生存率的概率随着每年存活时间的增加而增加。该列线图考虑了已经存活的年数,预测了食管癌手术后患者的生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/7af865ec2d1e/BJS-107-1053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/68c54027269c/BJS-107-1053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/7a5b2c13378b/BJS-107-1053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/7af865ec2d1e/BJS-107-1053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/68c54027269c/BJS-107-1053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/7a5b2c13378b/BJS-107-1053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/7317937/7af865ec2d1e/BJS-107-1053-g003.jpg

相似文献

1
Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.新辅助放化疗和手术治疗食管癌的条件生存。
Br J Surg. 2020 Jul;107(8):1053-1061. doi: 10.1002/bjs.11476. Epub 2020 Feb 3.
2
Individualized conditional survival nomograms for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and radical surgery.局部进展期直肠癌新辅助放化疗及根治术后患者个体化条件生存列线图
Eur J Surg Oncol. 2021 Dec;47(12):3175-3181. doi: 10.1016/j.ejso.2021.06.010. Epub 2021 Jun 6.
3
Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.基于国家数据登记处的食管或胃食管交界处癌症新辅助治疗的结果。
Br J Surg. 2016 Dec;103(13):1864-1873. doi: 10.1002/bjs.10304. Epub 2016 Sep 30.
4
External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.新辅助放化疗联合手术治疗食管癌患者术前病理肿瘤侵犯程度的外部验证。
Ann Surg Oncol. 2020 Apr;27(4):1250-1258. doi: 10.1245/s10434-019-08024-0. Epub 2019 Nov 5.
5
Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?新辅助放化疗治疗晚期食管癌患者 - 哪种反应分级系统对预后有最佳的区分作用?
Histopathology. 2019 Apr;74(5):731-743. doi: 10.1111/his.13811.
6
Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.新辅助放化疗对 cT3 期食管癌的预后影响——倾向评分匹配分析。
Eur J Cancer. 2014 Nov;50(17):2950-7. doi: 10.1016/j.ejca.2014.08.020. Epub 2014 Oct 9.
7
Thromboembolic and bleeding complications in patients with oesophageal cancer.食管癌患者的血栓栓塞和出血并发症。
Br J Surg. 2020 Sep;107(10):1324-1333. doi: 10.1002/bjs.11665. Epub 2020 May 19.
8
Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.新辅助放化疗联合食管癌切除术治疗癌症患者的淋巴结清扫数目对总生存率的影响:荷兰基于人群的队列研究。
Ann Surg. 2017 Nov;266(5):863-869. doi: 10.1097/SLA.0000000000002389.
9
Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.接受新辅助放化疗和手术的食管或食管胃交界癌患者的生存预测。
Br J Surg. 2016 Jul;103(8):1039-47. doi: 10.1002/bjs.10142. Epub 2016 Apr 26.
10
Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.新辅助放化疗与单纯化疗治疗食管癌:基于人群的队列研究。
Br J Surg. 2021 Apr 30;108(4):403-411. doi: 10.1093/bjs/znaa121.

引用本文的文献

1
Real-time survival assessment in breast cancer with liver metastasis.伴有肝转移的乳腺癌的实时生存评估
Discov Oncol. 2025 Jun 23;16(1):1184. doi: 10.1007/s12672-025-02999-x.
2
Trends in incidence, mortality, and conditional survival of anaplastic thyroid cancer over the last two decades in the USA.美国过去二十年间间变性甲状腺癌的发病率、死亡率及条件生存率趋势
Front Endocrinol (Lausanne). 2025 Jun 4;16:1585679. doi: 10.3389/fendo.2025.1585679. eCollection 2025.
3
Dynamic conditional survival nomogram for primary hepatocellular carcinoma: a population-based analysis.

本文引用的文献

1
A National Cohort Study Evaluating the Association Between Short-term Outcomes and Long-term Survival After Esophageal and Gastric Cancer Surgery.一项全国性队列研究评估了食管癌和胃癌手术后短期结局与长期生存的关系。
Ann Surg. 2019 Nov;270(5):868-876. doi: 10.1097/SLA.0000000000003520.
2
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.来源:基于登记处的转移性食管癌或胃癌患者总生存预测模型
Cancers (Basel). 2019 Feb 5;11(2):187. doi: 10.3390/cancers11020187.
3
Temporal Changes in Esophageal Cancer Mortality by Geographic Region: A Population-based Analysis.
原发性肝细胞癌的动态条件生存列线图:一项基于人群的分析。
Discov Oncol. 2025 May 21;16(1):854. doi: 10.1007/s12672-025-02642-9.
4
Dynamic assessment of long-term survival in survivors with stage III non-small cell lung cancer: a novel conditional survival model with a web-based calculator.III期非小细胞肺癌幸存者长期生存的动态评估:一种基于网络计算器的新型条件生存模型。
Front Med (Lausanne). 2025 Jan 7;11:1491337. doi: 10.3389/fmed.2024.1491337. eCollection 2024.
5
Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.接受CRS+HIPEC治疗的MPM患者长期生存的预后因素及条件生存分析:一项对两个中心的回顾性研究
Ann Surg Oncol. 2025 Apr;32(4):2912-2922. doi: 10.1245/s10434-024-16485-1. Epub 2024 Nov 13.
6
Conditional survival and changing risk profile in patients with gliosarcoma.胶质肉瘤患者的条件生存及风险特征变化
Front Med (Lausanne). 2024 Sep 6;11:1443157. doi: 10.3389/fmed.2024.1443157. eCollection 2024.
7
The conditional recurrence-free survival after R0 hepatectomy for locally advanced intrahepatic cholangiocarcinoma: A competing risk analysis based on inflammation-nutritional status.局部晚期肝内胆管癌R0肝切除术后的条件无复发生存率:基于炎症-营养状态的竞争风险分析
Heliyon. 2024 Jul 2;10(13):e33931. doi: 10.1016/j.heliyon.2024.e33931. eCollection 2024 Jul 15.
8
Individualized prediction of conditional survival for colorectal signet-ring cell carcinoma patients.结直肠癌印戒细胞癌患者条件生存的个体化预测
Ann Med Surg (Lond). 2024 Mar 25;86(5):2524-2530. doi: 10.1097/MS9.0000000000001982. eCollection 2024 May.
9
Conditional survival analysis and real-time prognosis prediction in stage III T3-T4 colon cancer patients after surgical resection: a SEER database analysis.III 期 T3-T4 结肠癌患者手术后的条件生存分析和实时预后预测:SEER 数据库分析。
Int J Colorectal Dis. 2024 Apr 19;39(1):54. doi: 10.1007/s00384-024-04614-x.
10
Dynamic estimates of survival in oncocytic cell carcinoma of the thyroid.甲状腺嗜酸细胞癌生存情况的动态评估
Discov Oncol. 2023 Nov 30;14(1):217. doi: 10.1007/s12672-023-00839-4.
按地理区域划分的食管癌死亡率的时间变化:基于人群的分析
Cureus. 2018 Nov 15;10(11):e3596. doi: 10.7759/cureus.3596.
4
Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer.列线图预测食管癌三联治疗后生存的验证。
Ann Thorac Surg. 2018 Nov;106(5):1541-1547. doi: 10.1016/j.athoracsur.2018.05.055. Epub 2018 Jun 19.
5
Prediction of Conditional Probability of Survival After Surgery for Gastric Cancer: A Study Based on Eastern and Western Large Data Sets.胃癌术后生存条件概率预测:基于东西方大数据集的研究。
Surgery. 2018 Jun;163(6):1307-1316. doi: 10.1016/j.surg.2018.02.011. Epub 2018 Apr 21.
6
Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis.食管癌或胃癌患者的预测模型:系统评价与荟萃分析
PLoS One. 2018 Feb 8;13(2):e0192310. doi: 10.1371/journal.pone.0192310. eCollection 2018.
7
A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis.胸段食管鳞状细胞癌新辅助放疗或放化疗后总生存的预后列线图:一项回顾性分析
Oncotarget. 2017 Jun 20;8(25):41102-41112. doi: 10.18632/oncotarget.17062.
8
Does neoadjuvant chemoradiotherapy increase survival in patients with resectable oesophageal cancer?新辅助放化疗能否提高可切除食管癌患者的生存率?
Interact Cardiovasc Thorac Surg. 2017 Jan;24(1):115-120. doi: 10.1093/icvts/ivw281. Epub 2016 Sep 13.
9
Survival After Surgical Resection of Stage IV Esophageal Cancer.IV期食管癌手术切除后的生存率
Ann Thorac Surg. 2017 Jan;103(1):261-266. doi: 10.1016/j.athoracsur.2016.06.070. Epub 2016 Sep 9.
10
Postoperative Complications and Long-Term Survival After Complex Cancer Resection.复杂癌症切除术后的并发症及长期生存情况
Ann Surg Oncol. 2017 Mar;24(3):638-644. doi: 10.1245/s10434-016-5569-5. Epub 2016 Sep 12.